Expanded Access Programs (EAPs) are increasingly recognized as an ethical imperative in modern healthcare. More companies are opening EAPs to provide critical therapies to patients who would otherwise lack access. […]

With Merck's acquisition of EyeBio for $1.3 Billion, Roche's Vabysmo launch success and multiple other phase II and III trials in DME, DR, RVO, and Wet AMD, there is plenty […]